Table 2.
Treatments and clinical outcomes of patients with COVID-19 receiving respiratory support
| All (n=289) |
Survivors (n=219) |
Fatal cases (n=70) |
P value* | |
| Treatments | ||||
| Antiviral therapy | ||||
| Lopinavir/ritonavir | 235 (81.3) | 182 (83.1) | 53 (75.7) | 0.228 |
| Darunavir/cobicistat | 42 (14.5) | 26 (11.9) | 16 (22.9) | 0.038 |
| Hydroxychloroquine | 187 (64.7) | 137 (62.6) | 50 (71.4) | 0.227 |
| Systemic glucocorticoid | 152 (52.6) | 96 (43.8) | 56 (80.0) | <0.001 |
| Intravenous immunoglobulin | 26 (9.0) | 16 (7.3) | 10 (14.3) | 0.124 |
| High–flow nasal cannula | 57 (19.7) | 19 (8.7) | 38 (54.3) | <0.001 |
| Invasive mechanical ventilation | 70 (24.2) | 38 (17.4) | 32 (45.7) | <0.001 |
| Continuous renal replacement therapy | 22 (7.6) | 5 (2.3) | 17 (24.3) | <0.001 |
| ECMO | 18 (6.2) | 10 (4.6) | 8 (11.4) | 0.074 |
| Clinical outcomes | ||||
| ICU admission | 96 (33.2) | 59 (26.9) | 37 (52.9) | <0.001 |
| Persistent hypotension | 77 (26.6) | 40 (18.3) | 37 (52.9) | <0.001 |
| ARDS | 113 (39.1) | 49 (22.4) | 64 (91.4) | <0.001 |
| Acute kidney injury | 52 (18.0) | 16 (7.3) | 36 (51.4) | <0.001 |
| Hospital stay, days | 25 (14–33) | 27 (19–37) | 10 (6–19) | <0.001 |
Data are expressed as median and IQR or numbers (%).
*Calculated by Student’s t test (or the Mann-Whitney U test, if appropriate) and χ2 test (or Fisher’s exact test, if appropriate).
ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.